EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic value of circulating glypican-4 in chronic heart failure

Nora Schwegel, Viktoria Höller, Viktoria Santner, David Kajetan Zach, Jakob Lugitsch, Axel Muendlein, Eva Maria Brandtner, Andreas Leiherer, Heinz Drexel, Arthur Mader, Andrea Borenich, Stefan Pilz und 7 weitere

Journal of Molecular Medicine · 2026-12 · 104 (1)

DOI: 10.1007/s00109-026-02667-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Medicine, online erschienen am 07.04.2026. Verfasst von Nora Schwegel und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University Heart Center Graz, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. Hauptthemen laut MEDLINE: Heart Failure, Glypicans. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Graz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glypican-4 (GPC-4), an endothelial cell surface protein, is released into the circulation in the context of ischemia, inflammation, neurohumoral activity, and shear stress. This study aimed to investigate the prognostic value of GPC-4 in chronic heart failure. GPC-4 concentrations were determined in two prospective cohorts: patients with chronic heart failure with reduced ejection fraction (HFrEF), and with transthyretin amyloid cardiomyopathy (ATTR-CM). Multivariable Cox regression analyses were adjusted for age, sex, estimated glomerular filtration rate, N-terminal B-type natriuretic peptide, and left ventricular ejection fraction. In HFrEF ( n = 205, median age 66 years, 22% women), 58 patients (28%) died, 18 (9%) from cardiovascular cause, and 46 patients (22%) were hospitalized for worsening heart failure (WHF) during 4.2 years follow-up. In ATTR-CM ( n = 121, median age 76 years, 12% women), 34 patients (28%) died, 12 (10%) from cardiovascular cause, and 32 patients (26%) had a WHF hospitalization during 2.2 years follow-up. Baseline GPC-4 (median [interquartile range]) levels were 1553 (1041, 1950) pg/ml in HFrEF, and 2071 (1579, 2893) pg/mL in ATTR-CM. In HFrEF, GPC-4 was independently associated with all-cause mortality (HR 1.69, 95%CI 1.22–2.32, p = 0.003) and cardiovascular mortality (HR 1.61, 95%CI 1.01–2.56, p = 0.045), but not with WHF hospitalizations. Conclusively, in ATTR-CM, GPC-4 independently predicted all-cause mortality (HR 1.96, 95%CI 1.12–3.44, p = 0.018), but not cardiovascular mortality and WHF hospitalizations. GPC-4 carries strong prognostic value for all-cause death in chronic heart failure across various etiologies, but not for heart-failure specific outcomes. Further studies are warranted to elucidate its value in cardiovascular disease. Key messages Glypican-4 rises with ischemia, inflammation, neurohumoral activity, and shear stress. Circulating glypican-4 predicts prognosis in chronic heart failure, regardless of cause. Glypican-4 predicted all-cause death in heart failure with reduced ejection fraction and restrictive cardiomyopathy, but not heart failure–specific outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureGlypicansHumansFemalePrognosisMaleAgedBiomarkersChronic DiseaseMiddle AgedStroke VolumeAged, 80 and overProspective Studies

Stichwörter der Autor:innen

Chronic heart failureGlypican-4Heart failure with reduced ejection fractionMortalityTransthyretin amyloid cardiomyopathy

Substanzen

GlypicansBiomarkers

Autor:innen und Institutionen

  • Division of Cardiology, University Heart Center Graz, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
  • Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
  • Institute for Medical Informatics, Statistics and Documentation, Medical University Graz, Graz, Austria.
  • Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Department of Internal Medicine With Cardiology, Nephrology and Intensive Care Medicine, University Hospital Wiener Neustadt, Wiener Neustadt, Austria.
  • Medical Faculty, Sigmund Freud University, Vienna, Austria.

Förderung

  • Medical University of Graz

Zitieren

APA

Schwegel, N., Höller, V., Santner, V., Zach, D. K., Lugitsch, J., Muendlein, A., Brandtner, E. M., Leiherer, A., Drexel, H., Mader, A., Borenich, A., Pilz, S., Grübler, M., Wallner, M., Ablasser, K., Kolesnik, E., Zirlik, A., von Lewinski, D., & Verheyen, N. (2026). Prognostic value of circulating glypican-4 in chronic heart failure. Journal of Molecular Medicine, 104(1). https://doi.org/10.1007/s00109-026-02667-9

Vancouver

Schwegel N, Höller V, Santner V, Zach DK, Lugitsch J, Muendlein A, et al. Prognostic value of circulating glypican-4 in chronic heart failure. Journal of Molecular Medicine. 2026;104(1). doi:10.1007/s00109-026-02667-9

BibTeX
@article{Schwegel2026,
  author = {Schwegel, Nora and Höller, Viktoria and Santner, Viktoria and Zach, David Kajetan and Lugitsch, Jakob and Muendlein, Axel and Brandtner, Eva Maria and Leiherer, Andreas and Drexel, Heinz and Mader, Arthur and Borenich, Andrea and Pilz, Stefan and Grübler, Martin and Wallner, Markus and Ablasser, Klemens and Kolesnik, Ewald and Zirlik, Andreas and von Lewinski, Dirk and Verheyen, Nicolas},
  title = {Prognostic value of circulating glypican-4 in chronic heart failure},
  journal = {Journal of Molecular Medicine},
  year = {2026},
  volume = {104},
  number = {1},
  doi = {10.1007/s00109-026-02667-9}
}
Kostenlos starten →